This study is to evaluate the efficacy and safety of different postoperative adjuvant regimens in patients with resectable adenocarcinoma of the esophagogastric junction who underwent radical surgery after neoadjuvant chemotherapy combined with immunotherapy and achieved pCR in postoperative pathology
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
500
SOX or XELOX plus PD-1 inhibitor
PD-1/PD-L1 monoclonal antibody
SOX or XELOX
Tegafur-Ugotex or Capecitabine
Compare the differences in the DFS rates between the two groups of subjects, DFS (Disease-Free Survival, which is the time from the start of postoperative adjuvant therapy until the first occurrence of recurrent disease
Time frame: The observation period starts from the time the postoperative adjuvant therapy begins and lasts for at least 2 years
Compare the differences in the OS rates between the two groups of subjects, OS (Overall Survival, which refers to the time from the start of postoperative adjuvant therapy until death due to any cause)
Time frame: The observation period starts from the time the postoperative adjuvant therapy begins and lasts for at least 2 years
The Adverse Events of anti-PD1/PDL1 monoclonal antibody combined with chemotherapy versus chemotherapy in postoperative adjuvant treatment for gastric cancer/adenocarcinoma of the esophagogastric junction
Time frame: The observation period starts from the time the postoperative adjuvant therapy begins and lasts for at least 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.